Pathfinder Cell Therapy, Inc.
Pathfinder Cell Therapy, Inc.
Your view on PFND
Overview
What the company does, where it operates, and who runs it.
About Pathfinder Cell Therapy, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard L. Franklin
- Headquarters
- 12 Bow Street, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard L. Franklin
- Headquarters
- 12 Bow Street, Cambridge, MA, US
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage.
It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Pathfinder Cell Therapy, Inc. from FRC's valuation model, read against the market price. PFND last traded at $0.0001; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Pathfinder Cell Therapy, Inc.. Starting points for Pathfinder Cell Therapy, Inc.: beta -24.33 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Pathfinder Cell Therapy, Inc.. Pathfinder Cell Therapy, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Pathfinder Cell Therapy, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Pathfinder Cell Therapy, Inc.. Pathfinder Cell Therapy, Inc. has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Pathfinder Cell Therapy, Inc. valued side by side against its closest peers. Pathfinder Cell Therapy, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Pathfinder Cell Therapy, Inc. executives and directors. Shares of Pathfinder Cell Therapy, Inc. have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Pathfinder Cell Therapy, Inc.. Coverage tracks Pathfinder Cell Therapy, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Pathfinder Cell Therapy, Inc.